Brodalumab, a novel biologic for people with moderate-to-severe psoriasis, receives positive opinion from European CHMP

Brodalumab, a novel biologic treatment for adult patients with moderate to severe plaque psoriasis, has been granted a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP), LEO Pharma has said. Brodalumab is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A. By binding to the receptor with high affinity, brodalumab effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis. Brodalumab is not currently licensed in the EU. The positive opinion from the CHMP is supported by data from three clinical trials, AMAGINE-1 (n=661), AMAGINE-2